IRCT20150206020981N5已完成1 期
Evaluation of safety and efficacy of focal intramuscular injection of wharton’s gelly-derived mesenchymal stem cell in Duchenne muscular dystrophy pediatrics between 4 to 20 years old
Sinacell Company0 个研究点目标入组 16 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 4 years 至 20 years（—）
- 性别
- Male
入选标准
- •Age between 4 to 20
- •Genetic evidence of Duchenne disease as a cause of myopathy
- •The patient's muscle strength is decreasing
- •Willingness and satisfaction to participate in the study by the patient's legal guardian in decision making and willingness to participate regularly in follow-up courses
- •Weight between 14 to 75
排除标准
- •A history of known malignancy
- •History of associated genetic and non-genetic degenerative diseases
- •A history of any other acute or chronic illness that, at the discretion of the clinician responsible for implementing the plan, prevents the patient from entering the study.
研究者
相似试验
招募中
2 期
Evaluation of safety and efficacy of focal intramuscular injection of wharton’s gelly-derived mesenchymal stem cell in Duchenne muscular dystrophy pediatrics between 5 to 12 years oldDuchenne muscular dystrophy.Muscular dystrophyG71.0IRCT20150206020981N4Sinacell Company5
招募中
不适用
Treatment of common wartsCTRI/2017/07/009028il50
招募中
不适用
Investigations on the efficacy and safety of intradermal injection of botulinum toxiDiseases of the skin and subcutaneous tissueKCT0004952Samsung Medical Center23
已完成
不适用
This study is to treat the melasma (black spots on face by giving intralesional tranexamic acid for treatment of melasma in male patientsCTRI/2019/07/020190Himachal Pradesh university58
尚未招募
不适用
Intramuscular glutathione as a systemic whitening agentPACTR201907742980888Sohag University Hospital30